Gene therapy is transforming what’s possible in modern medicine—reshaping patient outcomes, workforce health, and the long-term cost curve for employers. Yet these breakthroughs sit against the backdrop of rising health care costs. Join us for a forward-looking conversation with Madeline Bell, CEO of Children’s Hospital of Philadelphia (CHOP), whose leadership sits at the center of both dynamics. She will share a candid view on how a leading hospital navigates the real drivers of health care costs while pioneering some of the most significant clinical advances of the decade in pediatric medicine and gene therapy.
As part of our CEO in Health Care Series, presented in partnership with the Health Transformation Alliance, this session will give HR leaders unparalleled insight into how hospital innovation and hospital economics intersect—and what this means for the employer community.
Under Madeline Bell’s leadership, CHOP has emerged as a global leader in gene therapy discovery, development, and delivery, bringing life-changing treatments to children and accelerating the future of precision medicine. Her perspective on the rapidly advancing gene therapy landscape is uniquely valuable for HR leaders seeking to understand the implications for workforce health, benefits design, and long-term cost strategy. This session will offer participants a rare opportunity to learn directly from one of the field’s most influential and visionary leaders.
Ms. Bell will share a candid view on how a leading hospital navigates the real drivers of health care costs while pioneering some of the most significant clinical advances of the decade in pediatric medicine and gene therapy.
In our discussion, we will explore:
- Breakthrough Progress in Gene Therapy:
- How CHOP’s pioneering work is reshaping treatment pathways for rare and complex diseases — and what this means for the future of care.
- Implications for Employers and HR Leaders:
- What HR leaders need to understand about emerging gene therapies, their cost trajectory, and what they need to prepare for:
- Major shifts coming over the next 3–5 years:
- Ultra targeted therapies with high upfront costs but potentially curative outcomes
- Increasing access and equity considerations
- How to evaluate the value equation in a gene therapy world
- How employers can engage with health systems innovating at the genetic level
- The Evolving Health Care Landscape:
- How these transformative therapies will influence employee expectations, affordability challenges, and the role of employers in supporting access to high-value care.
Hosted jointly by the CHRO Association and the Health Transformation Alliance.
HTA Members who are not CHRO members, please reach out to Alexandria (atrujillo@chro.org) to register.
